Groningen Archives - CanPath - Canadian Partnership for Tomorrow’s Health

CanPath – Canadian Partnership for Tomorrow’s Health Search

About Us
- Purpose, Vision & Mission
  CanPath is working in partnership to prevent disease and provide a platform for scientists to conduct innovative research.
- Our History
  The Canadian Partnership Against Cancer established the Canadian Partnership for Tomorrow Project (now CanPath) in June 2008.
- Leadership & Governance
  Meet the members of CanPath's Leadership Team, Operations Committee, National Strategic Advisory Council and more.
- National Coordinating Centre
  Meet the members of CanPath's operational core, based at the University of Toronto's Dalla Lana School of Public Health.
- Student Work and Opportunities
  Students are a cornerstone of our population health research program, driving innovation and discovery as the next generation of researchers and health professionals.
- Regional Cohorts
  Seven regional cohorts across ten provinces comprise CanPath's pan-Canadian partnership.
- Funders & Supporters
  Learn more about the partner organizations that provide funding and in-kind support to CanPath.
- Frequently Asked Questions
  Find out how CanPath will improve the health of Canadians and more.
- Contact us
  How to reach CanPath by phone, email, in-person, or make a data access request.
Research
- About the Study
  CanPath is Canada’s largest population health cohort and a gateway platform to data worldwide.
- Access Process
  The CanPath Access Portal provides researchers with the necessary resources to identify epidemiological and biological data available from participating cohorts to answer innovative research questions.
- Approved Projects & Studies
  CanPath has supported more than 100 research projects and activities, many of which have resulted in publications in high impact journals.
- Publications
  These publications are examples of research made possible with data from CanPath and its regional cohorts.
- Funding & Grant Opportunities
  Supporting researchers and innovators who are seeking financial backing and collaborative opportunities for their projects utilizing CanPath data
- COVID-19 Initiatives
  As Canada’s largest population health study, CanPath responded quickly to the pandemic by leveraging its existing infrastructure to support national COVID-19 research.
- CanPath Student Dataset
  The CanPath Student Dataset provides students with the unique opportunity to gain hands-on experience working with CanPath data.
- Collaborations
  The CanPath team is committed to collaborating with partners in order to enhance and accelerate research for a healthier Canada.
Participants
- About the Study
  CanPath is Canada’s largest population health cohort and a gateway platform to data worldwide.
- Participant Snapshot
  Understand the unique social, economic and health characteristics of CanPath participants and how this information is captured for research.
- Meet CanPath Participants
  Hundreds of thousands of Canadians have come together to be part of a study that reveals real breakthroughs.
- COVID-19 Antibody Study FAQ
  CanPath and its regional cohorts are conducting a COVID-19 antibody study of 20,000 participants across Canada.
News & Events
CanPath Access Portal

Newest to Oldest
Oldest to Newest

2024

Estimating Additive Interaction in Two-Stage Individual Participant Data Meta-Analysis.

Authors: M. Basten, L. A. van Tuijl, K. Y. Pan, A. W. Hoogendoorn, F. Lamers, A. V. Ranchor, J. Dekker, P. Frank, H. Galenkamp, M. J. Knol, N. Noisel, Y. Payette, E. R. Sund, A. H. Zwinderman, L. Portengen, M. I. Geerlings

The researchers aimed to describe how the Relative Excess Risk due to Interaction (RERI) and other measures of additive interaction or effect modification can be validly estimated within two-stage individual participant data (IPD) meta-analysis. They proposed a three-step procedure to estimate additive interaction, and illustrate this procedure by investigating interaction between depression and smoking and risk of smoking-related cancers incidence during follow-up, and used IPD of six cohorts, including CARTaGENE.

Read Publication